Aim
Firstly, we aim to enhance the existing ActiveHip+ mHealth, which is currently focused on osteoporotic hip fractures, to provide lifestyle interventions (i.e., exercise, rehabilitation, nutrition and health education) for patients with hip and knee osteoarthritis, both before and after joint replacement surgery. For that purpose, we will conduct a co-creation study involving main stakeholders to include this new treatment content according to their needs. This expansion, called Recover+ will incorporate technological advancements such as an improved interface design and artificial intelligence to offer a more personalized monitoring and treatment system. Additionally, the content for lifestyle interventions will be translated and culturally adapted for use in Portugal,Italy and Switzerland.
Secondly, we will assess the feasibility of the Recover+ mHealth for treating osteoporotic hip fractures and hip/knee osteoarthritis in three Spanish hospitals, three Portuguese hospitals, and one Swiss hospital. A total of 396 patients and their family caregivers will be included, gathering data on the level of adoption, adherence, reach, and sustainability of the Recover+ mHealth. Moreover, it will be a useful way to get feedback on the system’s quality and satisfaction from patients, informal caregivers, and healthcare professionals. As part of the feasibility studies, we will also include an evaluation of clinical outcomes, cost-effectiveness and cost-utility outcomes.
Lastly, we will develop and execute implementation strategies, such as forming partnerships with osteoporosis and rheumatism patient associations, network with NGOs (e.g Frailty Fracture Network or European Alliance of Associations for Rheumatology EULAR), and conducting training sessions in hospitals. These efforts aim to facilitate the adoption of the Recover+ mHealth in the healthcare settings of Spain, Portugal, and Italy and Switzerland. All this will position us as the mHealth platform with the highest scientific rigour in Europe and provide a solid foundation for future expansions to clinical relevance to encompass a broader range of musculoskeletal conditions and decrease healthcare costs across different stakeholders.
Consortium
Fundacion Para La Investigacion Biosanitaria De Andalucia Oriental (ES) (Coordinator), Newel Health Srl (IT), Nursing School Of Lisbon (PT), Faculdade De Economia Universidade De Coimbra (PT), University of Geneva & University of Geneva Hospitals (CH), PP Pharmacie Principale SA (CH), RECOVER Injury Research Centre (Australia)
Swiss Principal Investigators
University of Geneva, Switzerland
Prof. Katarzyna Wac, GSEM, CUI, QoL Technologies Lab Director
University of Geneva Hospitals & University of Geneva, Switzerland
Prof. Didier Hannouche, MD, PhD, Chairman of the Department of Orthopedic Surgery, Director of the Cell Therapy & Musculoskeletal Disorders Lab, University of Geneva Hospitals (HUG) & Professor, Faculty of Medicine, University of Geneva
PP Pharmacie Principale SA, Switzerland
Mr. Jean-Philippe de Toledo, MBA, Directeur Général, Groupe Pharmacie Principale
Study recruitment: TBC, the project starts mid 2025 the latest.